ArticleJournal of translational medicine2014
Alpha fetoprotein DNA prime and adenovirus boost immunization of two hepatocellular cancer patients.
Article in Journal of translational medicine, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00093548 (A Phase I/II Trial Testing Immunization With AFP + GM-CSF Plasmid Prime And AFP Adenoviral Vector Boost In Patients With Hepatocellular Carcinoma), which is not on this map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Phase I/II Trial Testing Immunization With AFP + GM-CSF Plasmid Prime And AFP Adenoviral Vector Boost In Patients With Hepatocellular Carcinoma (AFP Prime-Boost Protocol)
Who cites it
34 citing papers in PubMed, 53 citations in OpenAlex.
- ARF6 promotes the nuclear translocation of β-catenin to facilitate AFP deficiency-mediated metastasis in CTNNB1Cell biology and toxicology · 2026Article
- Oncofetal reprogramming in hepatocellular carcinoma: linking developmental programs to cancer vaccines and immunotherapy.Clinical and molecular hepatology · 2026Review
- Tumor Vaccines in Hepatocellular Carcinoma: Advances, Challenges, and the Path Toward Precision Immunotherapy.Journal of clinical and translational hepatology · 2026Review
- Correlation of radiotherapy, targeted therapy, and immunotherapy with hepatocellular carcinoma recurrence.World journal of gastrointestinal oncology · 2025Review
- Immunotherapy and liver transplantation for hepatocellular carcinoma: Current and future challenges.World journal of transplantation · 2025Review
- Identification of tumor-specific neoantigens and immune clusters of hepatocellular carcinoma for mRNA vaccine development.Journal of cancer research and clinical oncology · 2023Article
- Immune-Based Combination Therapies for Advanced Hepatocellular Carcinoma.Journal of hepatocellular carcinoma · 2023Review
- Current insights into the hepatic microenvironment and advances in immunotherapy for hepatocellular carcinoma.Frontiers in immunology · 2023Review
- Production of a Novel Multi-Epitope Peptide Vaccine against Hepatocellular Carcinoma.Iranian journal of medical sciences · 2022Article
- Immunotherapy for hepatocellular carcinoma: A promising therapeutic option for advanced disease.World journal of hepatology · 2022Review
- Hepatocellular carcinoma and immunotherapy: Beyond immune checkpoint inhibitors.World journal of gastrointestinal oncology · 2022Article
- A brief review on DNA vaccines in the era of COVID-19.Future virology · 2021Review
- The Emerging Influences of Alpha-Fetoprotein in the Tumorigenesis and Progression of Hepatocellular Carcinoma.Cancers · 2021Review
- Insights into an Immunotherapeutic Approach to Combat Multidrug Resistance in Hepatocellular Carcinoma.Pharmaceuticals (Basel, Switzerland) · 2021Review
- Application of Immunotherapy in Hepatocellular Carcinoma.Frontiers in oncology · 2021Review
- Review
- New Aspects of Ultrasound-Mediated Targeted Delivery and Therapy for Cancer.International journal of nanomedicine · 2020Review
- The Potential Regulatory Roles of Circular RNAs in Tumor Immunology and Immunotherapy.Frontiers in immunology · 2020Review
- Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
Abstract
backgroundAlpha fetoprotein (AFP) is an oncofetal antigen over-expressed by many hepatocellular cancers (HCC). We previously demonstrated that HLA-A2-restricted epitopes derived from AFP are immunogenic in vitro and in vivo despite high circulating levels of this oncofetal antigen. In order to test a more broadly applicable, HLA-unrestricted, inexpensive, cell-free vaccine platform capable of activating tumor antigen-specific CD8+ and CD4+ T cells, we tested full length AFP in a plasmid DNA construct in combination with an AFP-expressing replication-deficient adenovirus (AdV) in a prime-boost vaccine strategy.
methodsHCC patients who had an AFP+ tumor and previous treatment for HCC were screened and two patients received vaccination with three plasmid DNA injections followed by a single AdV injection, all delivered intramuscularly (i.m.).
resultsThe vaccine was well tolerated and safe. Both patients showed immunologic evidence of immunization. The first patient had a weak AFP-specific T cell response, a strong AdV-specific cellular response and recurred with an AFP-expressing HCC at nine months. The second patient developed a strong AFP-specific CD8+ and CD4+ cellular response and an AdV neutralizing antibody response, and recurred at 18 months without an increase in serum AFP.
conclusionsThe AFP DNA prime-AdV boost vaccine was safe and immunogenic. Circulating anti-AdV neutralizing antibodies at baseline did not prohibit the development of AFP-specific cellular immunity. The patient who developed CD8+ and CD4+ AFP-specific T cell immunity had more favorable progression-free survival. The observations with these two patients support development of this vaccine strategy in a larger clinical trial.
trial registrationClinicalTrials.gov: NCT00093548.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.